The abstract is read at the publisher; the summary is JClub's.
A deep serum proteome signature of eight proteins distinguishes melanoma cases from matched controls within 1 year post diagnosis, achieving AUC 0.823 (95% CI 0.723–0.923).
- Why it matters: Early detection is critical for melanoma survival, but current screening relies on visual inspection and lacks clinically used serum protein biomarkers for early disease detection.
- What they did: In a Department of Defense Serum Repository longitudinal cohort (390 samples; 73 cases, 73 matched controls; up to four timepoints over 4 years before to 2 years after diagnosis), data independent acquisition mass spectrometry with nanoparticle protein enrichment was analyzed using random forest models with leave-one-out cross validation, univariate prefiltering, and Boruta feature selection.
- The result: Discrimination was weak before diagnosis (AUC 0.609 at 2 years and 0.566 at 4 years prior, with the latter not distinguishable from chance), while PRSS1 and PRSS2 recurred across cross-sectional and longitudinal models, supporting preliminary serum-based detection candidates pending external validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.